Review: Unlicensed NK Cells Target Neuroblastoma Following Anti-GD2 Antibody Treatment
Review: Unlicensed NK Cells Target Neuroblastoma Following Anti-GD2 Antibody Treatment Author: Tarek, N., et al. J. Clin. Invest. 2012; 122(9): 3260-3270. doi:10.1172/JCI62749. Background: Neuroblastoma (NB) is the most common childhood extracranial solid tumor. Nearly two-thirds of diagnosed patients exhibit poor long-term survival despite aggressive treatment approaches. Treatment with monoclonal antibodies against the disialoganglioside surface antigen GD2 has resulted in lower recurrence and improved survival. The anti-GD2 mAb 3F8 utilizes antibody-dependent cell-mediated toxicity (ADCC) via myeloid and natural killer (NK) cells to kill the neuroblastoma. […]